Vmbook Online ordering

Capstone Therapeutics Corp

Capstone Therapeutics Corp is a public company that was listed on the NASDAQ stock exchange under the ticker symbol "CPST" until its delisting in 2015. The company was focused on the development and commercialization of diseases affecting marginalized patient populations, including rare and orphan diseases.

Capstone's lead product candidate was a treatment for peripheral arterial disease (PAD), a condition that affects the blood flow to the legs and can result in pain, ulcers, and in severe cases, amputation. The company also had a pipeline of preclinical and discovery-stage product candidates targeting a range of other conditions, including fibrotic diseases and cancers.

However, Capstone faced significant challenges in developing and commercializing its products, including a lack of funding, changes in the regulatory environment, and competition from larger pharmaceutical companies. As a result, the company's stock price was highly volatile, and it was ultimately delisted from the NASDAQ in 2015.

Since then, Capstone has undergone significant changes and is now primarily focused on the development and commercialization of medical devices for wound care. The company's new lead product is a negative pressure wound therapy system for the treatment of chronic and acute wounds. Capstone is now traded over the counter under the ticker symbol "TPTZ."

It's worth noting that while I strive to provide accurate and up-to-date information, the stock market is subject to constant changes, and it's always a good idea to do your own research and consult with a financial advisor before making any investment decisions.